SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending on the back of positive preliminary results from its Phase III FLAMINGO-01 study, which showed an impressive ~80% reduction in breast cancer recurrence rates from its open-label arm. This news, coupled with an extended insider share lock-up, is fueling strong community confidence as investors actively discuss the potential for a significant short squeeze due to the stock's low float, high short interest, and soaring Cost To Borrow rates.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is experiencing intense volatility, largely driven by recent adjustments to futures margin requirements causing liquidations and a sharp price pullback. Community discussion is split between those calling it a 'blow-off top' and profiting from the decline, and others who see it as a manipulated 'bear trap,' pointing to underlying supply deficits and future export restrictions as powerful long-term catalysts.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is drawing significant attention with upcoming CES 2026 as a potential catalyst for new partnerships, alongside recent analyst upgrades pointing to its leading voice AI technology. While many investors highlight the company's strong fundamentals, including a substantial contractual backlog and no debt, community dialogue is split between optimism for a rebound and concerns over recent insider selling.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending on the back of explosive demand for its memory products, especially high-bandwidth memory (HBM), driven by the ongoing AI infrastructure build-out and data center expansion. The community is highly optimistic about Micron's future earnings and expanding gross margins, viewing it as a top AI beneficiary that remains undervalued despite its significant market performance.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is generating significant discussion as the critical PDUFA date for its innovative needle-free epinephrine oral film, Anaphylm, nears on January 31, 2026. The community expresses strong optimism, emphasizing the FDA's decision to forgo an Advisory Committee meeting as a key de-risking factor and highlighting Anaphylm's potential as a highly convenient, game-changing treatment for severe allergic reactions. Despite debates surrounding a competitor's petition and the stock's high short interest, many anticipate a positive approval and its significant market potential.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending due to a sharp pullback in gold and silver prices, which the community largely attributes to recent CME margin hikes on precious metals leading to forced liquidations. This has sparked intense debate among traders, with some viewing it as market manipulation and an opportunity to buy the dip, while others caution against chasing the top after a strong run.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is trending amid a dramatic surge in silver prices, largely attributed to escalating physical demand from China and anticipation of a potential Chinese export ban by early 2026. The community is highly engaged, with many predicting silver will reach unprecedented levels like $200-$1000 per ounce, fueled by a perceived short squeeze and vital industrial demand from AI and EV sectors. While AGQ's 2x leverage amplifies these movements, some traders caution about potential profit-taking and an overbought market after such a rapid ascent.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical (RARE) is trending due to the announcement that its Phase 3 trials for setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, causing a significant stock plunge. This was further impacted by a Complete Response Letter from the FDA for its UX111 gene therapy, citing manufacturing issues that are now being addressed. The community is sharply divided, debating if the steep sell-off is an overreaction and a potential buying opportunity, or if these setbacks signal deeper concerns for the rare disease focused company.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is seeing high discussion driven by persistent selling pressure, widely attributed by the community to ongoing share dilution from a Yorkville agreement and year-end tax-loss harvesting. Despite robust Q3 growth and recent Russell index inclusion, sentiment is deeply polarized, with many expressing frustration over continuous declines while others view current prices as a prime accumulation opportunity, frequently drawing comparisons to Robinhood's early trajectory amidst SPAC-related volatility.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively discussed amid multiple upcoming regulatory catalysts, including pivotal FDA decisions for tradipitant and Bysanti, alongside recent positive data for tradipitant addressing GLP-1 induced nausea and vomiting. The community views these events as high-stakes, potentially unlocking significant new markets and driving substantial upside, with many considering the stock deeply undervalued relative to its pipeline and cash position. While buyout speculation and management concerns persist, the overarching sentiment centers on the company's potential for a major re-rating as these binary events approach.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$FJET Day Traders... everywhere let&#39;s lock this Tiny FLOAT UP... in FJET StarFighters Space Inc New IPO... 
$NVDA $AAPL $TSLA $IONQ  
Good add spot today.

StockTwits Web

Starfighters Space Inc

Apple Inc

IonQ Inc

 Day Traders... everywhere let's lock this Tiny FLOAT UP... in FJET StarFighters Space Inc New IPO... 
